Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2023

United States118th CongressHR-3884House of Representatives
Updated: Sep 24, 2024

Summary

Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2023 This bill reauthorizes through FY2028 the Sickle Cell Disease Treatment Demonstration Program, which supports efforts to improve treatment and prevention of sickle cell disease and complications from that disease. (Sickle cell disease is an inherited blood disorder that can lead to pain, anemia, infections, and stroke.)

Bill texts

Available versions
View official text

3 versions available

Timeline

Latest companion bill action

S-1852: Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2023

Committee on Health, Education, Labor, and Pensions. Reported by Senator Sanders without amendment. Without written report.

  1. Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H5578)

  2. On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H5578)

    House of Representatives

  3. Motion to reconsider laid on the table Agreed to without objection.

    House of Representatives

  4. Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

    Senate